Colombia's court affirms use of compulsory licensing for HIV drug amid global IP tensions
Original framing: “STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine” — STAT News
Scientific evidence supports the efficacy of dolutegravir in treating HIV, and generic versions have been shown to be bioequivalent to the branded drug. The scientific community has long advocated for the use of generic alternatives to make treatment more accessible.
Colombia’s court ruling is a microcosm of a global struggle between corporate patent regimes and the right to health.
By examining the case through the lens of historical precedents, cross-cultural practices, and the voices of marginalized communities, we see a systemic failure in how intellectual property is governed. Indigenous knowledge, scientific evidence, and artistic resistance all point to the need for a more equitable health system. The solution lies not in isolated legal victories, but in structural reforms that prioritize human life over profit. This case is a call to re-imagine global health governance through a lens of justice, equity, and solidarity.